Biomimetic Synthesis and Biological Evaluation of Aplidiopsamine A

Joseph D. Panarese and Craig W. Lindsley*

Departments of Chemistry and Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States
craig.lindsley@vanderbilt.edu

Received September 6, 2012

Abstract

The first total synthesis of Aplidiopsamine A, a rare 3H-pyrrolo[2,3-c]quinoline alkaloid from the Aplidiopsis confluata, has been achieved following the proposed biosynthesis. This biomimetic synthesis requires only five steps and proceeds in 20.8% overall yield. Biological evaluation across large panels of discrete molecular targets identified that Aplidiopsamine A is a highly selective PDE4 inhibitor, a target for numerous CNS disorders.

The tricyclic 3H-pyrrolo[2,3-c]quinoline ring system is a rare moiety found only in a few marine natural products.1,2 The first members of this structural class were the marinoquinolines A–F (1–5), isolated from multiple species of bacteria and found to possess antibacterial, antifungal, and acetylcholinesterase activities (Figure 1).1,2 Several synthetic approaches to marinoquinolines A–C and E (1–3, 5) have been reported, relying on either a key Morgen–Walls or Pictet–Spengler reaction.3,4 Recently, aplidiopsamine A (6) was isolated from the Australian ascidian, Aplidiopsis confluata, and represents the first example of the 3H-pyrrolo[2,3-c]quinoline moiety linked to an adenine via a methylene bridge, a rare nonglycoside adenine conjugate. Thus, 6 represents only the second report of a marine organism producing the 3H-pyrrolo[2,3-c]quinoline ring system; importantly, 6 was found to be a potent antimalarial agent, without toxicity to healthy cells, further providing support for synthesis.5

Figure 1. Structures of the marinoquinolines A–F (1–5) and aplidiopsamine A (6), marine natural products possessing the rare 3H-pyrrolo[2,3-c]quinoline ring system (shown in red).

Carroll and co-workers developed a convergent biosynthetic proposal for 6 from adenine 7 and tryptophan 10 (Scheme 1). Here, 9 is generated from the reaction of adenine and hydroxyacetic acid. Pyrrole 11, itself a natural product isolated from R. thailandica, was postulated to be a dead-end product in the biosynthesis of pyrrolnitrin from tryptophan. Condensation of 9 and 11 would ultimately

lead to aplidiopsamine A, via a Bischler–Napieralski-like cyclization and dehydration sequence.\(^5\)

Therefore, we elected to pursue a biomimetic approach for the first total synthesis of aplidiopsamine A and attempt the condensation of a suitable synthetic surrogate of 9 and pyrrole 11 to access 12. Interestingly, Correia synthesized 11, en route to marinoquinolines A–C and E, from advanced materials in five synthetic steps in 47.5% overall yield.\(^6\) We envisioned a more expedited route and were gratified that a two-step sequence from commercial reagents produced 11. In the event, aniline 14 smoothly underwent a Suzuki coupling with boronate ester 13 to deliver TIPS protected pyrrole 15, which upon basic hydrolysis generated 11 in 96% yield over the two steps (Scheme 2).\(^6\) Acylation with α-bromo acetyl bromide provided 16 in 86% yield. Selective N-alkylation at the 9- versus 7-position of adenine to afford 12 was achieved via a hard deprotonation with NaH in 56% yield. Softer approaches with cesium carbonate resulted in 2:1 regioisomeric mixtures and poor conversion. With 12 in hand, we were now poised to perform the biomimetic condensation via a Bischler–Napieralski-type cyclization. Classical variants of this cyclization/dehydration sequence\(^7\) employ TFA, POCl\(_3\), or other Lewis acids; however, in the presence of the adenine moiety, these conditions either failed or led to intractable gums or poor conversion (less than 10% yields). Ultimately, we found that 4 M HCl/dioxanes under microwave irradiation (130 °C, 10 min) facilitated the reaction sequence to deliver, for the first time, aplidiopsamine A in 45% yield.\(^6\) Overall, the biomimetic synthesis of 6 required five steps and proceeded in 20.8% overall yield, an ideal route to prepare unnatural analogs.

The synthetic profile exhibited physical and spectroscopic data identical to those of the natural aplidiopsamine A.\(^5,6\) With large quantities of 6 in hand, we elected to further profile 6 against a larger panel of discrete molecular targets of therapeutic significance beyond antimalarial activity, as 6 was shown to be cytotoxic. Indeed, we have previously elucidated intriguing activities for a number of marine alkaloids at CNS targets with unprecedented selectivities among highly conserved receptor families.\(^8–11\) As 6 possesses the basic pharmacophore (H-bond donor/acceptor triad) of many known ATP-competitive kinase inhibitors,\(^12\) we profiled synthetic 6 in a KINOMEscan panel against 97 kinases (both wild-type and mutants) at a 10 μM concentration.\(^6,13\) Despite the presence of a known pharmacophore,\(^12\) 6 was uniformly inactive; however, this can also be viewed as possessing very clean ancillary pharmacology. In parallel, we also profiled 6 in a Lead Profiling screen (a radio ligand binding panel at a 10 μM concentration) against 68 GPCRs, ion channels, and transporters.\(^14\) Once again, 6 displayed very clean ancillary pharmacology, possessing activity at only two targets: 5-HT\(_{2B}\) (62% @ 10 μM) and PDE4/Rolipram (74% @ 10 μM). When full concentration–response curves (CRCs) were obtained for 6, the 5-HT\(_{2B}\) \(K_i\) was weak at ∼10 μM, but 6 proved to be a moderately potent PDE4 inhibitor (\(K_i = 1.2 \mu M\), \(IC_{50} = 3.3 \mu M\)).\(^6,14\) PDE4 is a high profile target for antidepressant, antipsychotic, and neuroprotective drug development.

\(^{(6)}\) See Supporting Information for full details.


![Scheme 1. Proposed Biosynthesis of Aplidiopsamine (6)](image)

![Scheme 2. Biomimetic Total Synthesis of Aplidiopsamine (6)](image)
development; moreover, 6 represents a fundamentally new PDE4 inhibitor chemotype.15,16

With the identification of a therapeutically relevant target for 6, the need emerged to develop rapid chemistry to enable the synthesis of unnatural analogs, and ideally, from a common intermediate. Application of our optimized cyclization/dehydration conditions with the advanced α-bromo intermediate 16 led directly to the 3H-pyrrolo[2,3-c]quinoline derivative 17, wherein the reaction conditions with HCl generated the corresponding chloromethyl congener (Scheme 3). Notably, high reaction temperatures typically employed in Bichler–Napieralski reactions were avoided as the condensation was found to proceed at room temperature. Compound 17 proved to be an ideal common intermediate for not only the synthesis of unnatural analogs of 6, compounds 18a–18c, in high yields (82–96%) but also the synthesis of marinoquinoline A (1) when the nucleophile was a hydride source, LiAlH4. This approach affords the natural product 1 in only five steps and in 52% overall yield, representing a highly expeditious route.3,4

With unnatural analogs of 6 in hand, we evaluated them against both rat PDE4 (Rolipram) and human PDE4 to discern structure–activity relationships (SAR). As shown in Table 1, several of the unnatural analogs possessed PDE4 activity but were weaker than 6 (rat Ki’s of 4.6 to 25 μM and IC50’s of 13 to 71 μM). All proved to be weaker functional antagonists on human PDE4 than rat. Interestingly, marinoquinoline A (1), lacking the amino methyl moiety at C9, was inactive as was the Bischler–Napieralski acyclic substrate 12, devoid of the 3H-pyrrolo[2,3-c]quinoline ring system. Overall, this suggests that the tricyclic 3H-pyrrolo[2,3-c]quinoline ring system with a C9 amino methyl moiety is essential for PDE4 activity, and this chemotype represents a fundamentally new PDE4 pharmacophore.

In summary, we have completed the first total synthesis of aplidiopsamine A (6) following the proposed biosynthetic pathway in five steps and with a 20.8% overall yield. Extensive biological profiling identified 6 as a moderately potent ligand for, and inhibitor of, PDE4, an important target for CNS drug discovery. These data further argue for natural products as a source of novel chemotypes to initiate drug discovery efforts. Furthermore, we developed chemistry to rapidly access unnatural analogs of 6 and also synthesized marinoquinoline A (1) in only five steps and in 52% overall yield. The SAR within this novel class of PDE4 ligands demonstrated that both the tricyclic 3H-pyrrolo[2,3-c]quinoline ring system and a C9 amino methyl moiety are required for PDE4 activity. Further refinements, DMPK analysis, and additional unnatural analog synthesis are underway and will be reported in due course.

**Acknowledgment.** This work was supported, in part, by the Department of Pharmacology and William K. Warren, Jr. Funding for the NMR instrumentation was provided in part by a grant from the NIH (S10 RR019022).

**Supporting Information Available.** Experimental procedures, characterization data, and 1H and 13C NMR spectra for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

The authors declare no competing financial interest.